HK1190930A1 - Uses of aromatic-cationic peptide - Google Patents
Uses of aromatic-cationic peptideInfo
- Publication number
- HK1190930A1 HK1190930A1 HK14104163.7A HK14104163A HK1190930A1 HK 1190930 A1 HK1190930 A1 HK 1190930A1 HK 14104163 A HK14104163 A HK 14104163A HK 1190930 A1 HK1190930 A1 HK 1190930A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- aromatic
- cationic peptide
- cationic
- peptide
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1019—Tetrapeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44477703P | 2003-02-04 | 2003-02-04 | |
US53569004P | 2004-01-08 | 2004-01-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1190930A1 true HK1190930A1 (en) | 2014-07-18 |
Family
ID=32853391
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK06112161.2A HK1090571A1 (en) | 2003-02-04 | 2006-11-03 | Methods for preventing mitochondrial permeability transition |
HK09110947.4A HK1131995A1 (en) | 2003-02-04 | 2006-11-03 | Methods for preventing mitochondrial permeability transition |
HK13105866.5A HK1178794A1 (en) | 2003-02-04 | 2013-05-17 | Methods for preventing mitochondrial permeability transition |
HK14104163.7A HK1190930A1 (en) | 2003-02-04 | 2014-04-30 | Uses of aromatic-cationic peptide |
HK15105970.6A HK1204999A1 (en) | 2003-02-04 | 2015-06-23 | Methods for preventing mitochondrial permeability transition |
HK15110675.4A HK1209652A1 (en) | 2003-02-04 | 2015-10-28 | Uses of aromatic-cationic peptide |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK06112161.2A HK1090571A1 (en) | 2003-02-04 | 2006-11-03 | Methods for preventing mitochondrial permeability transition |
HK09110947.4A HK1131995A1 (en) | 2003-02-04 | 2006-11-03 | Methods for preventing mitochondrial permeability transition |
HK13105866.5A HK1178794A1 (en) | 2003-02-04 | 2013-05-17 | Methods for preventing mitochondrial permeability transition |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15105970.6A HK1204999A1 (en) | 2003-02-04 | 2015-06-23 | Methods for preventing mitochondrial permeability transition |
HK15110675.4A HK1209652A1 (en) | 2003-02-04 | 2015-10-28 | Uses of aromatic-cationic peptide |
Country Status (14)
Country | Link |
---|---|
US (8) | US7576061B2 (xx) |
EP (9) | EP2491943B1 (xx) |
JP (7) | JP4838114B2 (xx) |
CN (3) | CN104225574B (xx) |
AU (1) | AU2004209663B2 (xx) |
CA (1) | CA2515080C (xx) |
CY (2) | CY1114959T1 (xx) |
DK (3) | DK2656854T3 (xx) |
ES (3) | ES2436011T3 (xx) |
HK (6) | HK1090571A1 (xx) |
HU (1) | HUE027110T2 (xx) |
PT (2) | PT2656854E (xx) |
SI (1) | SI2656854T1 (xx) |
WO (1) | WO2004070054A2 (xx) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2491943B1 (en) * | 2003-02-04 | 2018-10-10 | Cornell Research Foundation, Inc. | Methods for preventing mitochondrial permeability transition |
EP3167935B1 (en) | 2003-05-01 | 2018-07-18 | Cornell Research Foundation, Inc. | Method and carrier complexes for delivering molecules to cells |
RU2376028C2 (ru) | 2004-01-23 | 2009-12-20 | Корнелл Рисеч Фаундейшн, Инк. | Способ уменьшения окислительного повреждения (варианты) |
AU2014203126B2 (en) * | 2005-09-16 | 2016-03-10 | Cornell Research Foundation, Inc. | Methods for reducing cd36 expression |
CA2622911C (en) * | 2005-09-16 | 2016-12-06 | Cornell Research Foundation, Inc. | Methods for reducing cd36 expression |
ES2458870T3 (es) | 2008-02-07 | 2014-05-07 | Cornell University | Procedimientos para prevenir o tratar la resistencia a la insulina |
EP3741381B1 (en) | 2008-02-26 | 2024-04-24 | Cornell University | A peptide for use for prevention and treatment of acute renal injury |
DE102008061044A1 (de) * | 2008-12-11 | 2010-06-17 | Henkel Ag & Co. Kgaa | Zusammensetzung mit antioxidativ wirksamen Peptiden |
EP2408463B1 (en) * | 2009-03-20 | 2016-10-19 | The General Hospital Corporation d/b/a Massachusetts General Hospital | D-arg-2'6'-dimethyltyrosine-lys-phe-nh2 for use in the prevention and treatment of burn injuries and secondary complications |
CN107412724A (zh) * | 2009-08-12 | 2017-12-01 | 康奈尔大学 | 预防或治疗代谢综合症的方法 |
PT3708178T (pt) | 2009-08-24 | 2023-11-16 | Stealth Biotherapeutics Inc | Peptídeo para uso ao prevenir ou tratar a degeneração macular |
EP2944317A1 (en) * | 2009-10-05 | 2015-11-18 | Cornell University | Methods for the prevention or treatment of heart failure |
CA2786280A1 (en) * | 2009-12-31 | 2011-07-07 | Stealth Peptides International, Inc. | Methods for the prevention or treatment of vessel occlusion injury |
WO2011082328A1 (en) * | 2009-12-31 | 2011-07-07 | Stealth Peptides International, Inc. | Methods for performing a coronary artery bypass graft procedure |
JP2013518057A (ja) * | 2010-01-25 | 2013-05-20 | コーネル ユニヴァーシティー | 芳香族カチオン性ペプチドおよびその使用 |
WO2011106717A1 (en) * | 2010-02-26 | 2011-09-01 | University Of Florida Research Foundation, Inc. | Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy |
EP2808029A3 (en) * | 2010-03-15 | 2015-04-01 | Stealth Peptides International, Inc. | Combination therapies using cyclosporine and aromatic cationic peptides |
US20110245183A1 (en) * | 2010-04-06 | 2011-10-06 | Perricone Nicholas V | Topical Uses of Szeto-Schiller Peptides |
US20110245182A1 (en) * | 2010-04-06 | 2011-10-06 | Perricone Nicholas V | Topical Uses of Szeto-Schiller Peptides |
EP2942354A1 (en) * | 2010-05-03 | 2015-11-11 | Stealth Peptides International, Inc. | Aromatic-Cationic Peptides and Uses of Same |
CN106620645A (zh) * | 2010-07-09 | 2017-05-10 | 康德生物医疗技术公司 | 预防或治疗缺血/再灌注损伤之后无复流的方法 |
US20160176930A1 (en) | 2010-07-09 | 2016-06-23 | The Administrators Of The Tulane Educational Fund | Mu opioid receptor agonist analogs of the endomorphins |
WO2014137496A1 (en) * | 2013-03-08 | 2014-09-12 | The Administrators Of The Tulane Educational Fund | Mu opioid receptor agonist analogs of the endomorphins |
US20120083452A1 (en) * | 2010-09-30 | 2012-04-05 | Perricone Nicholas V | Topical Anesthetic Uses of Szeto-Schiller Peptides |
WO2012129427A2 (en) * | 2011-03-24 | 2012-09-27 | Cornell University | Aromatic-cationic peptides and uses of same |
JP2014527969A (ja) * | 2011-09-19 | 2014-10-23 | ジェンシア コーポレイション | 改変クレアチン化合物 |
CA3123992C (en) * | 2011-09-29 | 2024-06-04 | Mayo Foundation For Medical Education And Research | Aromatic-cationic peptides and methods for using same |
CN107261380A (zh) * | 2011-10-17 | 2017-10-20 | 康奈尔大学 | 芳香族阳离子肽及其用途 |
EP3009141A1 (en) * | 2011-12-09 | 2016-04-20 | Stealth Peptides International, Inc. | Aromatic-cationic peptides and uses of same |
AU2013237827B2 (en) * | 2012-03-30 | 2017-12-14 | Stealth Biotherapeutics Inc. | Methods and compositions for the prevention and treatment neuropathy |
CA2880648A1 (en) * | 2012-08-02 | 2014-02-06 | Stealth Peptides International, Inc. | Methods for treatment of atherosclerosis |
BR112015009072A2 (pt) * | 2012-10-22 | 2017-07-04 | Henry Ford Health Systems | métodos para redução dos riscos associados à insuficiência cardíaca e fatores associados à mesma |
WO2014134554A1 (en) * | 2013-03-01 | 2014-09-04 | Stealth Peptides International, Inc. | Methods and compositions for the prevention or treatment of barth syndrome |
CN116474071A (zh) * | 2013-03-01 | 2023-07-25 | 康德生物医疗有限公司 | 治疗线粒体疾病的方法 |
EP2989120A4 (en) | 2013-04-25 | 2017-04-19 | Carmel-Haifa University Economic Corp. | Synthetic anti-inflammatory peptides and use thereof |
WO2014209905A2 (en) | 2013-06-26 | 2014-12-31 | Stealth Peptides International, Inc. | Methods and compositions for detecting and diagnosing diseases and conditions |
US20160193278A1 (en) * | 2013-08-01 | 2016-07-07 | Stealth Biotherapeutics Corp | Methods and compositions for preventing or treating leber's hereditary optic neuropathy |
CA2920020C (en) | 2013-08-02 | 2023-03-14 | Stealth Biotherapeutics Corp | Methods and compositions for the prevention and treatment of friedreich's ataxia |
US20160375088A1 (en) * | 2013-09-30 | 2016-12-29 | Brian Yinge ZHAO | Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity |
EP3154694A1 (en) | 2014-06-13 | 2017-04-19 | Children's Medical Center Corporation | Products and methods to isolate mitochondria |
WO2015197723A1 (en) | 2014-06-25 | 2015-12-30 | Flamma S.P.A. | Process for preparing d-arginyl-2,6-dimethyl-l-tyrosyl-l-lysyl-l-phenylalaninamide |
ES2890676T3 (es) | 2014-06-30 | 2022-01-21 | Flamma Spa | Procedimiento para la producción de D-arginil-2,6-dimetil-L-tirosil-L-lisil-L-fenilalaninamida |
WO2016004093A2 (en) * | 2014-07-01 | 2016-01-07 | Stealth Biotherapeutics Corp | Therapeutic compositions including galectin-3 inhibitors and uses thereof |
CN104306954B (zh) * | 2014-09-25 | 2016-08-24 | 中山大学 | Wry三肽在制备治疗阿尔茨海默症药物中的用途 |
EP3212194A4 (en) | 2014-10-29 | 2018-06-20 | University Of Maryland | Methods of treating age-related symptoms in mammals and compositions therefor |
WO2017015660A1 (en) * | 2015-07-23 | 2017-01-26 | Salk Institute For Biological Studies | Prevention and treatment of aging and neurodegenerative diseases |
WO2017093897A1 (en) * | 2015-11-30 | 2017-06-08 | Peter Schiller | Aromatic-cationic peptides conjugated to antioxidants and their use in treating complex regional pain syndrome |
CN115160402A (zh) * | 2016-03-11 | 2022-10-11 | 隐形生物治疗公司 | 结晶盐形式 |
US10870678B2 (en) | 2016-04-11 | 2020-12-22 | Arcuate Therapeutics, Inc. | Chiral peptides |
WO2018100893A1 (ja) | 2016-11-30 | 2018-06-07 | 株式会社ダイセル | 撮像装置用レンズモジュール及びその製造方法 |
US11034724B2 (en) | 2017-04-05 | 2021-06-15 | Stealth Biotherapeutics Corp. | Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2 |
WO2019033330A1 (en) | 2017-08-17 | 2019-02-21 | Xw Laboratories, Inc. | PREPARATION AND USES OF DERIVATIVES TRACERS OF OXYGEN REACTIVE SPECIES |
JP6976618B2 (ja) | 2017-09-04 | 2021-12-08 | エックスダブリューファルマ リミテッド | 活性酸素種スカベンジャーの調製および使用 |
JP6958860B2 (ja) * | 2017-11-07 | 2021-11-02 | 学校法人自治医科大学 | ミトコンドリアの機能障害の改善剤、及びミトコンドリアの機能障害に起因する疾患又は症状の予防又は治療薬、並びにそれらの用途 |
US10676506B2 (en) | 2018-01-26 | 2020-06-09 | Stealth Biotherapeutics Corp. | Crystalline bis- and tris-hydrochloride salt of elamipretide |
US20220041653A1 (en) * | 2018-12-18 | 2022-02-10 | Stealth Biotherapeutics Corp. | Mitochondria-targeting peptides |
EP3962365A4 (en) * | 2019-05-02 | 2023-02-01 | Children's Medical Center Corporation | THERAPEUTIC AND PROPHYLACTIC USE OF MITOCHONDRIA AND COMBINED MITOCHONDRIAL AGENTS |
EP3771467A1 (en) | 2019-07-30 | 2021-02-03 | Fundacio Institut de Recerca de l'Hospital de la Santa Creu i sant Pau | Ss-31 for the prevention and/or treatment of aneurysm |
CA3191819A1 (en) | 2020-09-09 | 2022-03-17 | Hazel Szeto | Methods and compositions for delivery of biotin to mitochondria |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US5602100A (en) | 1988-06-30 | 1997-02-11 | Astra Ab | Dermorphin analogs having pharmacological activity |
ES2085865T3 (es) | 1988-06-30 | 1996-06-16 | Astra Ab | Analogos de dermorfina, sus metodos de preparacion, composiciones farmaceuticas, y metodos de tratamiento terapeutico que los emplean. |
US5674980A (en) | 1989-12-21 | 1997-10-07 | Biogen Inc | Fusion protein comprising tat-derived transport moiety |
ATE165208T1 (de) * | 1990-01-17 | 1998-05-15 | Univ California | Zusammensetzung zur verbesserung der lebenserhaltung biologischer materialien |
US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
US5716644A (en) | 1992-06-11 | 1998-02-10 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
US5674534A (en) | 1992-06-11 | 1997-10-07 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
IS4261A (is) | 1994-02-21 | 1995-08-22 | Astra Aktiebolag | Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra |
DE69630918T2 (de) * | 1995-06-09 | 2004-10-28 | Hisamitsu Pharmaceutical Co., Inc., Tosu | Matrix für Iontophorese |
US5849761A (en) | 1995-09-12 | 1998-12-15 | Regents Of The University Of California | Peripherally active anti-hyperalgesic opiates |
DE69722258T2 (de) * | 1996-10-07 | 2004-03-18 | Eli Lilly And Co., Indianapolis | Neue verbindungen nutlich als neuroschützende mittel |
US5885958A (en) | 1997-03-25 | 1999-03-23 | Administrators Of The Tulane Educational Fund | Mu-opiate receptor peptides |
US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
US6221355B1 (en) | 1997-12-10 | 2001-04-24 | Washington University | Anti-pathogen system and methods of use thereof |
US6268398B1 (en) * | 1998-04-24 | 2001-07-31 | Mitokor | Compounds and methods for treating mitochondria-associated diseases |
US6472378B2 (en) * | 1998-08-31 | 2002-10-29 | Pro-Neuron, Inc. | Compositions and methods for treatment of mitochondrial diseases |
US6245740B1 (en) | 1998-12-23 | 2001-06-12 | Amgen Inc. | Polyol:oil suspensions for the sustained release of proteins |
GB9905503D0 (en) * | 1999-03-10 | 1999-05-05 | Adprotech Plc | Novel compound formulations and methods of delivery |
SE9900961D0 (sv) | 1999-03-16 | 1999-03-16 | Astra Ab | Novel compounds |
JP2003511362A (ja) * | 1999-10-04 | 2003-03-25 | ユニバーシティー オブ メディシン アンド デンティストリー オブ ニュー ジャージー | 新規カルバメートおよび尿素類 |
US6759520B1 (en) * | 1999-10-28 | 2004-07-06 | The New England Medical Center Hospitals, Inc. | Chimeric analgesic peptides |
US20050192215A1 (en) | 2000-01-21 | 2005-09-01 | Malabika Ghosh | Methods and materials relating to novel polypeptides and polynucleotides |
EP1303186B1 (en) * | 2000-07-18 | 2011-01-26 | Cornell Research Foundation, Inc. | Medicinal uses of mu-opioid receptor agonists |
US6900178B2 (en) | 2000-09-12 | 2005-05-31 | University Of Kentucky Research Foundation | Protection against ischemia and reperfusion injury |
WO2002044126A2 (en) * | 2000-11-28 | 2002-06-06 | Guilford Pharmaceuticals Inc. | Bisubstituted carbocyclic cyclophilin binding compounds and theirus |
US6545097B2 (en) * | 2000-12-12 | 2003-04-08 | Scimed Life Systems, Inc. | Drug delivery compositions and medical devices containing block copolymer |
CA2435829A1 (en) * | 2001-01-25 | 2002-08-01 | Guilford Pharmaceuticals Inc. | Trisubstituted carbocyclic cyclophilin binding compounds and their use |
US20030077826A1 (en) * | 2001-02-02 | 2003-04-24 | Lena Edelman | Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC) |
AU2002247153A1 (en) * | 2001-02-16 | 2002-09-04 | Cordis Corporation | Balloon catheter stent delivery system with ridges |
AU2002252372A1 (en) * | 2001-03-16 | 2002-10-03 | Sts Biopolymers, Inc. | Stent with medicated multi-layer hydrid polymer coating |
JPWO2002102833A1 (ja) * | 2001-06-15 | 2004-09-30 | 千寿製薬株式会社 | 新規エンドモルフィン誘導体 |
CN100536909C (zh) * | 2003-02-04 | 2009-09-09 | 科内尔研究基金会 | 用于防止线粒体通透性改变的方法 |
EP2491943B1 (en) * | 2003-02-04 | 2018-10-10 | Cornell Research Foundation, Inc. | Methods for preventing mitochondrial permeability transition |
EP3167935B1 (en) | 2003-05-01 | 2018-07-18 | Cornell Research Foundation, Inc. | Method and carrier complexes for delivering molecules to cells |
JP2005005762A (ja) * | 2003-06-09 | 2005-01-06 | Fujitsu Ltd | 送信電力制御方法及び装置 |
US7232824B2 (en) | 2003-09-30 | 2007-06-19 | Scios, Inc. | Quinazoline derivatives as medicaments |
RU2376028C2 (ru) * | 2004-01-23 | 2009-12-20 | Корнелл Рисеч Фаундейшн, Инк. | Способ уменьшения окислительного повреждения (варианты) |
CA2622911C (en) | 2005-09-16 | 2016-12-06 | Cornell Research Foundation, Inc. | Methods for reducing cd36 expression |
-
2004
- 2004-02-03 EP EP11009660.9A patent/EP2491943B1/en not_active Expired - Lifetime
- 2004-02-03 PT PT131780439T patent/PT2656854E/pt unknown
- 2004-02-03 EP EP18199147.2A patent/EP3479838A1/en not_active Withdrawn
- 2004-02-03 CA CA2515080A patent/CA2515080C/en not_active Expired - Lifetime
- 2004-02-03 EP EP20210900.5A patent/EP3842055A1/en active Pending
- 2004-02-03 EP EP04707809.2A patent/EP1599216B9/en not_active Expired - Lifetime
- 2004-02-03 CN CN201410412683.1A patent/CN104225574B/zh not_active Expired - Lifetime
- 2004-02-03 JP JP2006503317A patent/JP4838114B2/ja not_active Expired - Lifetime
- 2004-02-03 PT PT47078092T patent/PT1599216E/pt unknown
- 2004-02-03 ES ES04707809T patent/ES2436011T3/es not_active Expired - Lifetime
- 2004-02-03 EP EP17192437.6A patent/EP3305313A1/en not_active Withdrawn
- 2004-02-03 ES ES13178043.9T patent/ES2540897T3/es not_active Expired - Lifetime
- 2004-02-03 EP EP14186875.2A patent/EP2865385B1/en not_active Expired - Lifetime
- 2004-02-03 AU AU2004209663A patent/AU2004209663B2/en not_active Expired
- 2004-02-03 EP EP19207802.0A patent/EP3659618A1/en not_active Withdrawn
- 2004-02-03 EP EP16192437.8A patent/EP3144009A1/en not_active Withdrawn
- 2004-02-03 SI SI200432258T patent/SI2656854T1/sl unknown
- 2004-02-03 ES ES14186875.2T patent/ES2605504T3/es not_active Expired - Lifetime
- 2004-02-03 DK DK13178043.9T patent/DK2656854T3/en active
- 2004-02-03 CN CN2012100218642A patent/CN102617706A/zh active Pending
- 2004-02-03 EP EP20130178043 patent/EP2656854B1/en not_active Expired - Lifetime
- 2004-02-03 DK DK14186875.2T patent/DK2865385T3/en active
- 2004-02-03 US US10/771,232 patent/US7576061B2/en active Active
- 2004-02-03 DK DK04707809.2T patent/DK1599216T3/da active
- 2004-02-03 CN CN201210177633.0A patent/CN102784383B/zh not_active Expired - Lifetime
- 2004-02-03 HU HUE13178043A patent/HUE027110T2/en unknown
- 2004-02-03 WO PCT/US2004/003193 patent/WO2004070054A2/en active Application Filing
-
2006
- 2006-06-30 US US11/427,804 patent/US7718620B2/en active Active
- 2006-11-03 HK HK06112161.2A patent/HK1090571A1/xx not_active IP Right Cessation
- 2006-11-03 HK HK09110947.4A patent/HK1131995A1/xx not_active IP Right Cessation
-
2010
- 2010-04-02 US US12/753,403 patent/US20100190718A1/en not_active Abandoned
- 2010-10-28 JP JP2010241738A patent/JP5775285B2/ja not_active Expired - Lifetime
-
2011
- 2011-09-28 US US13/247,648 patent/US8404646B2/en not_active Expired - Lifetime
-
2013
- 2013-02-27 US US13/778,994 patent/US8957030B2/en not_active Expired - Lifetime
- 2013-05-17 HK HK13105866.5A patent/HK1178794A1/xx not_active IP Right Cessation
- 2013-09-03 JP JP2013182343A patent/JP5837542B2/ja not_active Expired - Lifetime
-
2014
- 2014-01-24 CY CY20141100064T patent/CY1114959T1/el unknown
- 2014-04-30 HK HK14104163.7A patent/HK1190930A1/xx not_active IP Right Cessation
- 2014-10-01 JP JP2014202889A patent/JP6126059B2/ja not_active Expired - Lifetime
-
2015
- 2015-01-13 US US14/595,946 patent/US20150359838A1/en not_active Abandoned
- 2015-06-23 HK HK15105970.6A patent/HK1204999A1/xx not_active IP Right Cessation
- 2015-07-06 JP JP2015135207A patent/JP6166312B2/ja not_active Expired - Lifetime
- 2015-08-03 CY CY20151100675T patent/CY1116575T1/el unknown
- 2015-10-28 HK HK15110675.4A patent/HK1209652A1/xx not_active IP Right Cessation
-
2017
- 2017-02-15 JP JP2017025764A patent/JP2017095519A/ja active Pending
-
2019
- 2019-01-08 JP JP2019001256A patent/JP2019089773A/ja active Pending
- 2019-09-12 US US16/569,573 patent/US20200038472A1/en not_active Abandoned
-
2022
- 2022-02-10 US US17/668,744 patent/US20230293624A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1209652A1 (en) | Uses of aromatic-cationic peptide | |
IL172403A0 (en) | D-amino acid peptides | |
GB0226251D0 (en) | Acetylated protein | |
AU2003290563A8 (en) | Leptin-related peptides | |
EP1578787A4 (en) | NOVEL PEPTIDES OF CHI-CONOTOXIN (-II) | |
HK1090065A1 (en) | Preparation of somatostatin peptides | |
GB0324265D0 (en) | Peptide | |
EP1486507A4 (en) | PEPTIDE INHIBITOR OF TRANSMEMBRANE NFAT | |
EP1614695A4 (en) | POLYPEPTIDE | |
GB0324457D0 (en) | Modified peptides and their uses | |
GB0202275D0 (en) | Peptide | |
GB0203453D0 (en) | Peptide synthesis | |
GB0205206D0 (en) | Synthetic peptides | |
GB0210746D0 (en) | Peptide | |
EP1699809A4 (en) | PEPTIDE FROM AMNIOTIC LIQUID AND USES THEREOF | |
GB0312352D0 (en) | Oxidation of peptides | |
GB0305552D0 (en) | Purification of peptides | |
GB0322317D0 (en) | Expansin polypeptide | |
GB0219980D0 (en) | Peptides | |
GB2415195B (en) | Peptides of IRF-1 | |
GB0203883D0 (en) | Peptide | |
GB0326303D0 (en) | Peptides | |
GB0324466D0 (en) | Peptides | |
GB0224896D0 (en) | Peptides | |
GB0213246D0 (en) | Peptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PE | Patent expired |
Effective date: 20240202 |